35Pharma
About 35Pharma
The startup specializes in designing potent ligand traps through protein engineering and an in-depth understanding of transforming growth factor-beta structure-function relationships, targeting pulmonary hypertension and musculoskeletal disorders. This approach enables the development of biologics that effectively address the unmet medical needs of patients suffering from these conditions.
<problem> Pulmonary hypertension, cardiometabolic diseases, and musculoskeletal disorders represent significant unmet medical needs, often driven by imbalances in the transforming growth factor-beta (TGF-β) superfamily signaling pathways. Current treatments may not effectively target the underlying causes of these diseases or may have limited efficacy and significant side effects. </problem> <solution> 35Pharma is developing best-in-class ligand traps that selectively neutralize validated pathological TGF-β superfamily ligands, while sparing beneficial homeostatic ligands. The company leverages its expertise in protein engineering and TGF-β biology to design innovative biologics that address the root causes of these diseases. Their lead candidates, HS135 and HS235, are designed to inhibit Activin and growth differentiation factor (GDF) signaling, offering potential therapeutic benefits in pulmonary hypertension, cardiometabolic disease, and obesity. HS235 has demonstrated promising pre-clinical results, including improved body composition and rescued left ventricular function in obese heart failure models. </solution> <features> - Rationally designed ligand traps with high potency and selectivity for TGF-β superfamily ligands - HS135: An Activin inhibitor in clinical development for pulmonary hypertension - HS235: A novel Activin and GDF inhibitor in Phase 1 clinical trials for cardiometabolic disease and obesity - Demonstrated pre-clinical efficacy of HS235 in improving body composition and cardiac function in obese HFpEF models - Potential for combination therapy with GLP-1 receptor agonists for enhanced fat-selective weight loss - Proprietary protein engineering platform for generating novel biologics with optimized manufacturability </features> <target_audience> The primary target audience includes patients suffering from pulmonary hypertension, cardiometabolic diseases, and obesity, as well as physicians and healthcare providers seeking more effective and targeted therapies for these conditions. </target_audience>
What does 35Pharma do?
The startup specializes in designing potent ligand traps through protein engineering and an in-depth understanding of transforming growth factor-beta structure-function relationships, targeting pulmonary hypertension and musculoskeletal disorders. This approach enables the development of biologics that effectively address the unmet medical needs of patients suffering from these conditions.
Where is 35Pharma located?
35Pharma is based in Montréal, Canada.
How much funding has 35Pharma raised?
35Pharma has raised 366990000.
- Location
- Montréal, Canada
- Funding
- 366990000
- Employees
- 39 employees
- Major Investors
- Frazier Life Sciences